Oestrogen receptor α mediates 17β-estradiol enhancement of ovarian cancer cell motility through up-regulation of survivin expression

Archives of Gynecology and Obstetrics

Volumn 286, Issue 3, 2012, Pages 729-737

  Zhu, Jing ^a   Lu, Xin ^a   Hua, Ke Qin ^a   Sun, Hong ^a   Yu, Yin Hua ^a   Feng, You J ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

17 estradiol; Migration; Oestrogen receptor ; Ovarian cancer; RNAi; Survivin

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MESSENGER RNA; SURVIVIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL INVASION; CELL LEVEL; CELL MIGRATION; CELL MOTILITY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CORRELATION; GENETIC TRANSFECTION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MULTICENTER STUDY; OVARY CANCER; RNA INTERFERENCE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DNA, COMPLEMENTARY; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MCF-7 CELLS; MICE; NIH 3T3 CELLS; OVARIAN NEOPLASMS; TRANSFECTION; UP-REGULATION;

EID: 84867997992     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2368-5     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics 2000. CA Cancer J Clin 50:7-33
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics 2007. CA Cancer J Clin 57:43-66
3. Scully RE (1995) Pathology of ovarian cancer precursors. J Cell Biochem Suppl 23:208-218 (Pubitemid 26032877)
4. Perniconi SE, Simöes MJ, Simöes RS, Haidar MA, Baracat EC, Soares Junior JM (2008) Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens. Clinics 63:381-388
5. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61:6768-6776 (Pubitemid 32896499)
6. Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A (2001) Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J Soc Gynecol Investig 8:104-113 (Pubitemid 32385404)
7. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F et al (1998) Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367-5373 (Pubitemid 28551118)
8. Twal WO, Czirok A, Hegedus B, Knaak C, Chintalapudi MR, Okagawa H et al (2001) Fibulin-1 suppression of fibronectinregulated cell adhesion and motility. J Cell Sci 114:4587-4598 (Pubitemid 34082877)
9. Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N, Garcia M (2001) Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Steroid Biochem Mol Biol 76:119-124 (Pubitemid 32510673)
10. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460-1465 (Pubitemid 32221894)
11. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SAA, Pettinger M et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative Randomized Trial. JAMA 290:1739-1748 (Pubitemid 37430624)
12. Li F, Altieri DC (1999) The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 59:3143-3151 (Pubitemid 29316014)
13. Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164-171 (Pubitemid 44485888)
14. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y et al (1910) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 1346-1353:2000
15. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2117:2613-2622 (Pubitemid 34478319)
16. Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediat Surg 418:1431-1440 (Pubitemid 44080254)
17. Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC et al (1087) Transgenic expression of surviving in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 991-999:2001
18. Yamamoto T, Manome Y, Nakamura M, Tanigawa N (2002) Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 3817:2316-2324 (Pubitemid 35346474)
19. Ryan BM, O'Donovan N, Duffy MJ (2009) Survivin: A new target for anti-cancer therapy. Cancer Treat Rev 35:553-562
20. Hua KQ, Feng WW, Cao Q, Zhou XR, Lu X, Feng YJ (2008) Estrogen and progestin regulate metastasis through the PI3K/ AKT pathway in human ovarian cancer. Int J Oncol 33:959-967
21. Ai ZH, Yin LH, Zhou XR, Zhu Y, Zhu DM, Yu YH, Feng YJ (2006) Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107:746-756 (Pubitemid 44232667)
22. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS et al (2007) Survivin expression in ovarian cancer. Exp Oncol 29:121-125 (Pubitemid 47310506)
23. Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L et al (2005) Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosisrelated parameters. Br J Cancer 92:271-277 (Pubitemid 40343140)
24. Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, Nesland JM et al (2007) Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109:228-238 (Pubitemid 46106237)
25. Qian X, Xi X, Li L (2011) Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol 19:126-132
26. Johnson ME, Howerth EW (2004) Survivin: A bifunctional inhibitor of apoptosis protein. Vet Pathol 41:599-607 (Pubitemid 39573750)
27. Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou AM, Tsipis A et al (2008) The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 204:241-249 (Pubitemid 351377530)
28. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al (2002) Human survivin is negatively regulated by wild type p53 and participate in p53-dependent apoptotic pathway. Oncogene 2:2613-2622 (Pubitemid 34478319)
29. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M (2002) Transcriptional repression of the anti-apoptotic survivin gene wild type p53. J Biol Chem 277:3247-3257 (Pubitemid 34953189)
30. Robertson JFR (2001) ICI 182,780 (Fulvestrant TM)-the first oestrogen receptor down-regulator-current clinical data. Brit J Cancer 85(Suppl 2):11-14 (Pubitemid 33753504)
31. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574 (Pubitemid 37204856)
32. Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K et al (2005) Anti-proliferative effect of estrogen in breast cancer cells that re-express ERa is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol 34:535-551 (Pubitemid 40585200)
33. Yu L, Wang CY, Shi JD, Miao L, Du XL, Mayer D et al (2011) Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. Endocrinology 152:773-781
34. Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzani AR, Simoncini T (2010) Estrogen receptor-a promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24:2114-2125
35. Pennati M, Folini M, Zaffaroni N (2007) Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis 28:1133-1139 (Pubitemid 47062670)
36. McManus M, Sharp P (2002) Gene silencing in mammals by small interfering RNAs. Genetics 3:737-747
37. Hojilla CV, Mohammed FF, Khokha R (2003) Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89:1817-1821 (Pubitemid 37533251)